alexa Mousemodel For Testing Anti-Dux4 Therapies For FSHD
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Cell & Gene Therapy
October 27-29, 2014 Embassy Suites Las Vegas, USA

Abhijit Dandapat, Robert Arpke, Darko Bosnakovski, Lynn Hartweck, Kristen A Baltgalvis, Derek Vang, Megan Roth, June Baik, Radbod Darabi, Rita C R Perlingeiro, Dawn A Lowe, Kent Hamra, Kalpna Gupta and Michael Kyba
Accepted Abstracts: J Stem Cell Res Ther
DOI: 10.4172/2157-7633.S1.009
(FSHD) patients typically suffer from asymmetric muscle loss with age and the disease is associated with genomic alterations that lead to dominant expression of the toxic DUX4 protein. To generate an animal model to study the effects of DUX4, a doxycycline-inducible transgene encoding DUX4 and 3? genomic DNA was introduced into a euchromatic region of the mouse X chromosome. Surprisingly, without induction, DUX4 RNA was expressed at low levels in many tissues and animals displayed a variety of unexpected dominant leaky phenotypes, including male-specific lethality. Occasional live-born males were expressed DUX4 RNA at low levels but did not show signs of dystrophy before they died by 4-6 weeks of age. To study the effects of DUX4 expression on muscle regeneration, this lethality was bypassed by isolating and transplanting iDUX4 satellite cells from iDUX4 males. In the presence of doxycycline, it was observed a dose-dependent suppression of new fiber formation by transplanted satellite cells. Data on the use of this conditional model to test anti-DUX4 therapeutics, specifically gene therapy targeting the DUX4 message in transplanted satellite cells will be presented. This approach, using the first transgenic mouse model to show pathologies due to FSHD-related D4Z4 sequences, allows quantitative testing of therapies for FSHD directed against DUX4.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version